{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:25:00Z","timestamp":1792167900650,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1344,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/annonc\/mdv603","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T04:50:11Z","timestamp":1450414211000},"page":"502-508","source":"Crossref","is-referenced-by-count":40,"title":["A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Isayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fukuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv603_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdv603_bb0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv603_bb0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv603_bb0025","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0030","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","author":"Morizane","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdv603_bb0040","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bjc.2015.103","article-title":"Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"112","author":"Ohkawa","year":"2015","journal-title":"Br J Cancer"},{"issue":"Suppl. 4","key":"10.1093\/annonc\/mdv603_bb0045","article-title":"Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer","volume":"31","author":"Mizuno","year":"2013","journal-title":"In J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0050","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2004.03.104","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis","volume":"22","author":"Thirion","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0055","first-page":"393","article-title":"Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice","volume":"2","author":"Tsukioka","year":"2009","journal-title":"Mol Med Rep"},{"key":"10.1093\/annonc\/mdv603_bb0060","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0065","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdp371","article-title":"Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer","volume":"21","author":"Koizumi","year":"2010","journal-title":"Ann Oncol"},{"issue":"Suppl. 4","key":"10.1093\/annonc\/mdv603_bb0070","article-title":"Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China","volume":"30","author":"Denda","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0075","first-page":"99","article-title":"S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol","volume":"17","author":"Hironaka","year":"2016"},{"key":"10.1093\/annonc\/mdv603_bb0080","doi-asserted-by":"crossref","unstructured":"Wang-Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2015 Nov 29 [epub ahead of print], doi:10.1016\/S0140-6736(15)00986-1.","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"10.1093\/annonc\/mdv603_bb0085","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdt166","article-title":"Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials","volume":"24","author":"Rahma","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv603_bb0090","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv603_bb0095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ajcn\/64.4.552","article-title":"Serum albumin is associated with skeletal muscle in elderly men and women","volume":"64","author":"Baumgartner","year":"1996","journal-title":"Am J Clin Nutr"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/3\/502\/16699888\/mdv603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:50:28Z","timestamp":1624693828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419355991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0923753419355991"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv603","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}